These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 2936166

  • 1. Clinical application of prostaglandin E1 in cases of occlusive arterial disease.
    Mishima Y.
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():547-8. PubMed ID: 2936166
    [Abstract] [Full Text] [Related]

  • 2. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
    Trübestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, Horsch S, Kriessmann A, Maass U, Martin M.
    Vasa Suppl; 1989; 28():44-9. PubMed ID: 2692200
    [Abstract] [Full Text] [Related]

  • 3. Intraarterial prostaglandine E1 in arterial occlusive disease (AOD) stages III and IV.
    Herold A, Bruch HP, Hörl M, Düsel W.
    Prog Clin Biol Res; 1987; 242():439-44. PubMed ID: 2959966
    [Abstract] [Full Text] [Related]

  • 4. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
    Fitscha P, Simmet T, Peskar BA, Reuter H, Sinzinger H, Rogatti W, Tilsner V.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):477-81. PubMed ID: 3062905
    [Abstract] [Full Text] [Related]

  • 5. [Prostaglandin E1 in decreased arterial perfusion].
    Pilger E, Bertuch H, Stark G, Hönigl K.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):490-5. PubMed ID: 3062908
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostaglandin E1 in chronic arterial disease: a multicenter study.
    Trübestein G, Diehm C, Gruss JD, Horsch S.
    Prog Clin Biol Res; 1987 Jul 15; 242():445-51. PubMed ID: 3313418
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K, Rogatti W, Rüttgerodt K.
    Vasa Suppl; 1989 Jul 15; 28():31-8. PubMed ID: 2609242
    [Abstract] [Full Text] [Related]

  • 9. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
    Sinzinger H, Rogatti W.
    Wien Klin Wochenschr; 1991 Jul 15; 103(18):558-65. PubMed ID: 1750223
    [Abstract] [Full Text] [Related]

  • 10. [Double-blind placebo-controlled study of the behavior of tcPO2 during intravenous infusion of prostaglandin E1 in patients with severe arterial occlusive disease].
    Creutzig A, Caspary L, Alexander K.
    Vasa Suppl; 1992 Jul 15; 35():36-8. PubMed ID: 1481055
    [No Abstract] [Full Text] [Related]

  • 11. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.
    Creutzig A, Arnold A, Caspary L, Thum J, Alexander K.
    Angiology; 1995 May 15; 46(5):357-67. PubMed ID: 7741319
    [Abstract] [Full Text] [Related]

  • 12. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
    Heidrich H.
    Vasa Suppl; 1991 May 15; 33():346-7. PubMed ID: 1788752
    [Abstract] [Full Text] [Related]

  • 13. Intermittent intraarterial infusion therapy with PGE1 in patients with severe claudication--results of a randomized prospective double blind study.
    Caspary L, Creutzig A, Radeke U, Specht S, Alexander K.
    Biomed Biochim Acta; 1988 May 15; 47(10-11):S307-10. PubMed ID: 3073766
    [Abstract] [Full Text] [Related]

  • 14. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y, Shiokawa Y, Homma M, Kashiwazaki S, Ichikawa Y, Hashimoto H, Sakuma A.
    J Rheumatol; 1987 Feb 15; 14(1):97-101. PubMed ID: 3553591
    [Abstract] [Full Text] [Related]

  • 15. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S, Mizushima Y, Aihara H, Yokoyama K, Watanabe M, Yanagawa A.
    Drugs Exp Clin Res; 1985 Feb 15; 11(9):627-31. PubMed ID: 3880049
    [Abstract] [Full Text] [Related]

  • 16. [Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease].
    Stiegler H, Diehm C, Grom E, Martin M, Mörl H, Rudofsky G, Vogelberg KH.
    Vasa Suppl; 1992 Feb 15; 35():164-6. PubMed ID: 1481031
    [No Abstract] [Full Text] [Related]

  • 17. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
    Matsui K, Ikeda U, Murakami Y, Yoshioka T, Shimada K.
    Am Heart J; 2003 Feb 15; 145(2):330-3. PubMed ID: 12595852
    [Abstract] [Full Text] [Related]

  • 18. [Pharmacologic concepts for clinical use of prostaglandin E1].
    Schrör K.
    Vasa Suppl; 1991 Feb 15; 33():335-6. PubMed ID: 1788746
    [Abstract] [Full Text] [Related]

  • 19. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
    Weiss T.
    Vasa; 2003 Nov 15; 32(4):187-92. PubMed ID: 14694766
    [Abstract] [Full Text] [Related]

  • 20. [Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental--results of a multicenter double-blind study].
    Rudofsky G, Haussler KF, Künkel HP, Schneider-May H, Spengel F, Symann O, Werner HJ, Rössner M.
    Vasa Suppl; 1987 Nov 15; 20():375-8. PubMed ID: 3321494
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.